133286Detection of cancer mutations in blood using an innovative DNA sequencing technologyClosedFeasibility StudiesInnovate UKCancer treatment has changed radically with the introduction of targeted drugs guided by mutation testing. Alterations in genes have been validated as powerful predictive biomarkers in the management of various cancers where mutation testing is currently the standard to personalise treatment decisions. It is well documented that a broad spectrum of cancers release DNA into peripheral blood (ctDNA). There is a growing interest in use of ctDNA as a non-invasive biomarker to detect the presence of cancer, follow treatment response, gauge prognosis, and monitor for recurrence. Next Generation Sequencing (NGS) has revolutionised genomic exploration and is driving the implementation of precision diagnostics. However, the sensitivity and accuracy of current NGS methods is compromised by sequencing errors. This is a fundamental limitation, particularly when aiming to identify rare mutants in genetically heterogeneous mixtures, such as ctDNA. To overcome this limitation, GeneFirst has developed an improved NGS technology with increased sensitivity and accuracy for the concurrent detection of multiple mutations. This new technology is suitable for the use of liquid biopsy (i.e. blood), enabling clinically relevant cancer genotyping by non-invasive means.